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FK506 and cyclosporine were used for the prevention 
of acute graft-versus-host disease. Acute GVHD was 
induced in Lewis rats by total-body irradiation and sub-
sequent reconstitution with allogeneic (ACI) bone mar-
row and spleen cells (BMTx). GVHD was assessed by 
both clinical and histologic parameters during the ex-
periment duration of 60 days, and longer for selected 
animals. All untreated BM recipients died within 26 
days from severe acute GVHD. GVHD was prevented 
with CsA during the period of immunosuppressive ther-
apy, but it appeared within a few days afterward. 
FK506-treated BM recipients were also protected, but 
they had a markedly prolonged GVHD-free period after 
therapy was discontinued. Most such animals eventually 
developed GVHD but with notable exceptions. Mainte-
nance therapy with doses of FK506 as low as 0.1 mg/kg 
every other day (1120 of daily induction dose) was infal-
lible insurance against delayed GVHD. The relevance of 
these findings to GVHD caused by lymphoid-containing 
solid organs such as the intestine was discussed. 
Graft-versus-host disease is a systemic manifestation of al-
loactivation of transplanted lymphoid cells to recipient alloan-
tigens (1,2). Cutaneous, gastrointestinal, pulmonary, and he-
patic manifestations of GVHD can be subdivided into acute 
and chronic forms, which represent a continuum of immune-
regulated injury. Various immunosuppressive strategies have 
been used to prevent or treat GVHD in humans, but none are 
completely satisfactory. 
We have evaluated the new immunosuppressive drug, FK506 
(3), as well as cyclosporine, for the prevention of acute GVHD 
after transplantation of fully allogeneic bone marrow plus 
spleen cells in a rat model (BMTx). The ACI to Lewis donor! 
recipient strain combination is fully MHC and non-MHC dis-
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parate, and this technique of lymphoid transplantation results 
in uniform mortality from GVHD in untreated recipients. 
MATERIALS AND METHODS 
Experimental procedures. Male Lewis (RTl') and male ACI (RTla) 
rats weighing 200-225 g (Harlan Sprague Dawley, Indianapolis, IN) 
were maintained in a laminar-flow caging system. They were given 
acidified water containing neomycin sulfate (10 mg/L) and were fed 
rat chow, ad libitum. Bone marrow was harvested from the tibias and 
femurs of ACI donor rats, washed, and resuspended in Hanks' balanced 
salt solution supplemented with gentamicin (50 Itg/ml). In addition, 
single-cell suspensions were prepared from ACI donor spleens. A total 
of 60Xl06 ACI BM cells and 30Xl06 ACI spleen cells were infused via 
the penile vein of Lewis recipients, 2 hr after they had been given 1000 
rads total-body irradiation from a l37Cs source. After the bone marrow-
splenocyte transplantation (referred to as BMTx), the animals were 
given penicillin/streptomycin/gentamicin on day 0, followed by genta-
micin injections on days 1 and 2. 
The FK506 and CsA were given by intramuscular injection once a 
day unless noted otherwise. FK506 powder (Fujisawa Pharmaceutical 
Company, Osaka, Japan) with carrier solvent HCO-60 and D-mannitol 
was diluted in normal saline. Cyclosporine (Sandoz Pharmaceuticals, 
Hanover, NJ) was dissolved in Intralipid, to a concentration of 15 
mg/ml or 25 mg/ml. 
With either drug, daily treatment was for 7 or 14 days, starting on 
day 3 after BMTx (Table 1). One group of animals also received a 
prolonged course of every-other-day therapy with FK506 out to 60 
days; at which time, some of the animals were sacrificed to search for 
histologic evidence of GVHD. Controls are summarized in Table 1. 
TABLE 1. Experimental groups 
Group Reconstitution Immunosuppression mg/kg Days of therapy No. 
1 None None 5 
2 Lewis BM None 5 
3 ACIBM None 10 
4 ACIBM CsA 15 3-9 10 
5 ACIBM CsA 25 3-9 10 
6 ACIBM FK506 1 3-9 10 
7 ACIBM FK506 1 3-9 10 
0.1 q.o.d. 12-60 
8 ACIBM FK506 0.1 3-16 10 
9 ACIBM FK506 1.0 3-16 10 
10 ACIBM FK506 1.5 3-16 10 
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TABLE 2. Grading of graft-versus-host diseasea 
Histopathologic parameters 
Severity 
Ear/tongue Liver Small intestine 
-------
+ (1) Basal vacuolar degeneration and 
necrosis of the epidermis 
(1) Mild lymphocyte infiltration of 
the bile ductules 
(1) Apoptosis in epithelium 
(2) Mild lymphocyte infiltration of 
the epidermis 
(2) Mild bile ductular injury (2) Multiple cryptitis (>3 crypts per 
high -power field) 
(3) Inflammation of lamina propria 
++ (1) Eosinophilic necrosis, spon-
giosis, dyskeratosis 
(1) Moderate lymphocyte infiltra-
tion of the bile ducts 
(1) As per (+), plus one individual 
crypt loss per high-power field 
(2) Massive lymphocyte infiltration 
of 
(2) Moderate bile duct damage 
+++ (1) Focal microscopic epidermal! (1) As per (++), plus >3 crypt loss 
dermal separation per high-power field 
a Three parameters required to be graded positive for GVHD_ Clinical GVHD parameters include the following: erythematous ear, hyperkeratosis 
of the footpad, dermatitis, weight loss, unkempt appearance, and diarrhea. 
These included irradiation alone (1000 rads TBI, without BM rescue), 
syngeneic BMTx (1000 rads TBI plus syngeneic Lewis BM), and 
allogeneic BMTx without drug treatment (1000 rads TEl plus alloge-
neic ACI BM). 
Determination of GVHD. Assessment of G VHD was done with formal 
criteria (Table 2), with body-weight measurement every 3 days and 
surveillance daily for clinical signs of GVHD. Clinical GVHD was 
diagnosed when at least 3 of the physical findings described in Table 2 
were present. Weekly ear biopsies were taken from 3 or 4 anima.!s in 
each experimental group. When the terminal stages of GVHD were 
reached, all such animals were sacrificed, and samples were obtained 
of skin, tongue, liver, and small bowel. The histopathologic grading 
(Table 2) was done independently by two pathologists (AJD, WM) 
without knowledge of the experimental group. 
Determination of chimerism. Four weeks after BMTx, ACI (donor) 
and Lewis (original recipient) phenotypes were assessed by surface-
marker analysis of 5x105 lymphoid cells from the recipient peripheral 
blood of 3 rats in each group following Ficoll-Hypaque gradient cen-
trifugation and resuspension of the cells in HBSS. Three different 
monoclonal antibodies were used to detect MHC class I antigens. MAb 
163 (IgG2b) is a monoclonal antibody that is specific for the RTl.N 
haplotype expressed on Lewis cells, while MAb 211 (lgG2b) is specific 
for the RTl.N haplotype expressed on ACI cells. MAb 42 is a mono-
clonal directed against RTl.An haplotype and served as the control. All 
antibodies were kindly provided by H. W. Kunz, University of Pitts-
burgh, Department of Pathology, Pittsburgh, PA; they have been 
previously characterized (4, 5). These primary biotinylated monoclonal 
antibodies were used at a 1:50 dilution, incubated for 60 min at 4'C, 
washed twice with HBSS containing 0.1 % gelatin, and resuspended 
with FITC-avidin as a secondary marker. After 1 hr incubation at 4'C, 
the cells were washed 3 times with HBSS plus 0.1 % gelatin with a final 
suspension in 1 % paraformaldehyde. Triplicate cell suspensions were 
analyzed on a fluorescence-cell analyzer (Coulter Epics, Hialeah, FL). 
Statistical analysis. Survival was calculated by the life-table method, 
with the mean survival time (MST)" being derived from that at which 
50% of the animals were surviving. In this study, animals living >60 
days were considered long-term survivors, and the survival time was 
defined as 60 days. Comparisons of the MST were analyzed using a 
two-tailed Student's t test, with unequal variances. P values <0.05 were 
considered statistically significant. 
RESULTS 
Chimerism. By 3-4 weeks after allogeneic BMTx, more than 
95% of the lymphocytes in the Lewis recipients bore ACI 
• Abbreviation: mean survival time. 
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FIGURE 1. Flow cytometric analysis of cell phenotypes from control 
(Lew, left and ACI, middle) and a representative chimeric bone marrow 
transplant rat (right). 
phenotypes in all tested animals (Fig. 1). After more than 60 
days, 4 long survivors were randomly phenotyped with the same 
results indicating the stability of the chimeric state. As controls, 
Lewis animals reconstituted with syngeneic BM cells showed 
only Lewis RT1.A' phenotypes (data not shown). 
Survival and clinical GVHD. The mean survival of 12 days 
after irradiation alone (group 1) was increased by allogeneic 
BMTx (group 3), but all these animals died of acute GVHD in 
less than 26 days (Table 1). Syngeneic BMTx rescued all 
animals (group 2). 
In allogeneic BMTx recipients, a 7-day course of 15 or 25 
mg/kg/day CsA for 7 days delayed the appearance of GVHD, 
but all animals developed this complication after stopping 
treatment (Table 3) and died soon after (groups 4 and 5). 
FK506 at doses of 1 mg/kg/day for the same interval was more 
effective (group 6). Even using 1/10 this dose for 14 days, ame-
lioration of GVHD was evident but of brief duration after the 
drug was stopped (group 8). Doses of lor 1.5 mg/kg/day for 14 
days extended the GVHD-free interval even more, as well as 
survival (groups 9 and 10), and at the higher dose 90% of 
animals did not have GVHD during the 60 days of the study. 
The GVHD-free interval after stopping therapy was related to 
the induction dose and was significantly longer with each dose 
increment (P<0.005) in groups 8-10. However, when animals 
had only a I-week course of 1 mg/kg/day plus continued 
supplementary maintenance doses (0.1 mg/kg) every other day 
for 60 days (group 7), all survived throughout the study without 
GVHD (Table 1). 
At the conclusion of the 60-day study, 22 rats without clinical 
evidence of GVHD were alive. Two were sacrificed for tissue 
studies, leaving 20. During the next 40 days off all therapy, 17 
of the residual group died, and delayed GVHD was responsible 
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TABLE 3. Onset of GVHD and survival 
Group Therapy Mg/kg/day Days of therapy % With i.m. after BM GVHD 
GVHD 
median days 
to onset 
Days surviving 
Mean 
survival 
time 
p Versus group 
1 None 11, 11, 12, 13, 13 12.0 
2 None all >60 >60 
3 None 100 10 17, 19, 19, 20, 20, 20, 22, 21.1 
24, 25, 25 
4 CsA 15 3-9 100 17 22, 31, 31, 31, 31, 31, 31, 30.2 <0.005 3 
31,31,32 
5 CsA 25 3-9 100 25 25, 28, 32, 32, 32, 32, 32, 31.6 <0.005 3 
32,32,39 
6 FK506 1 3-9 70 50 38, 51, 52," 52, 52, 52, 52.3 <0.005 4 
52, 54, >60, >60 <0.005 5 
7 FK506 1 3-9, then 0.1 0 ALL >60 (n = 3) >60 <0.005 6 
mg/kg 
8 FK506 0.1 3-16 100 25 31, 31, 31, 31, 31, 31, 31, 31 <0.005 3 
31, 31, 31 
9 FK506 1.0 3-16 90 52 46, 52,· 58,· 58,· 58, 58, 56 <0.005 7 
58, 58, 58, >60 8 
10 FK506 1.5 3-16 10 58 58, >60, >60, >60, >60, >60 11 
>60, >60, >60, >60, 
>60 
a Animals died without clinical symptoms of GVHD. 
TABLE 4. Histologic grading of GVHD during and following cessation of immunosuppression 
mg/kg/day Days of Grading of Grading of GVHD at autopsy Group Therapy therapy after GVHDduring i.m. BM treatment-eara Ear Tongue Liver Intestine 
1 None 
2 None 0 0 NA' NA NA 
3 None 2d 2d 3d 2d 2d 
4 CsA 15 3-9 0 1d 2d 0 1d 
5 esA 25 3-9 0 0-ld 1-2d 0 0-1 d 
6 FK506 1 3-9 0 0-1 d 1-2d 0 0-1 d 
7b FK506 1 3-9,then 0 0 1d 0 0 
0.1 q.o.d. 
8 FK506 0.1 3-16 0 1-2d 2d 2d 1d 
9 FK506 1.0 3-16 0 0-ld 1-2d 0 0-ld 
10 FK506 1.5 3-16 0 0 NA NA NA 
a Biopsies taken on the last day of treatment. 
b Two animals were sacrificed at 60 days for tissue analysis, reported in the autopsy grading of GVHD. The remaining animals were followed 
until 100 days. 
C NA: not available. 
d Animals died without clinical symptoms of GVHD. 
for the mortality in nearly all the animals. By 100 days, 3 
animals were left, 2 from groups 7 and one from group 10. 
Histopathologic studies. Both esA and FK506 prevented his-
topathologic evidence of G VHD during active treatment (Table 
4), but afterward lesions began to appear, even in some animals 
without clinical evidence of GVHD. The greatest freedom from 
GVHD lesions was in the continuous FK506-therapy rats 
of group 7 and the high 14-day dose FK506 rats of group 10 
(Fig. 2). 
DISCUSSION 
The effectiveness of esA in preventing GVHD in rats was 
described in 1979, using a less-severe model than that of the 
present study (6). In the earlier work, BM cells alone were 
transplanted in contrast to the bone marrow-splenocyte com-
bination that we employed. The mortality from GVHD with 
our modification of BMTx was uniform in untreated animals, 
with well-documented histologic GVHD found in all organ 
systems analyzed. A short course of esA did not lead to toler-
ance, and G VHD was noted in all animals within two weeks 
after cessation of induction therapy. All died from GVHD 
within 40 days. 
FK506 given for the same period of time appeared to be more 
effective, but here also the delayed appearance of GVHD was 
the rule after discontinuance of therapy. However, administra-
tion of small doses of maintenance FK506 every other day was 
capable of suppressing GVHD once the induction period was 
completed. It is noteworthy that FK506 can reverse established 
graft-versus-host disease in the same experimental model (7) 
and ameliorate chronic GVHD in humans (8). 
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FIGURE 2. Effect of low-dose continuous treatment with FK506 on 
the development of GVHD. Histology of target organs from an animal 
treated with FK506 at 1.0 mg/kg followed by 0.1 mg/kg/q.o.d. (group 
With any immunosuppressive regimen, the difficulty of 
achieving permanent graft acceptance of bone marrow without 
continuing therapy is similar to that with heart (9) and most 
other kinds of solid organ grafts. In contrast is the ease in the 
same rat-strain combination with which livers can be trans-
planted under FK506 (9). Nevertheless, the seemingly perma-
nent acceptance of BM in a small number of our rats suggests 
that the objective of permanent graft acceptance across a strong 
histocompatibility barrier could be within grasp in animals or 
in patients. 
Insight about how to achieve a stable chimeric state may 
come from a better understanding of the events following 
transplantation of "difficult" solid organs such as the intestine, 
which contain a large lymphoid mass. It was shown recently in 
rats (10) and humans (11) treated with FK506 that the lym-
phoreticular population of intestinal grafts was replaced com-
pletely over several postoperat.ive weeks with cells of recipient 
phenotype while the epithelial cells remained of donor origin. 
At the same time in the patients (11), donor lymphocytes in 
large numbers were detectable in the peripheral blood, meaning 
that the traffic in the graft lymphoid tissue was two way. The 
absence of either graft rejection or G VHD during this extraor-
dinary cell repopulation or afterward under FK506 was not 
7). Biopsies of (A) ear, (B) tongue, (C) liver, and (D) small bowel were 
taken 60 days after BMTx. There was no histological evidence of 
G VHD, except for foci of lymphocytic exocytosis, seen in the tongue. 
thought to be drug specific but rather a function of the drug's 
potency. How to control the repopulation process reliably is 
the practical question under investigation. In the meanwhile, 
it seems clear that a drug like FK506 can reduce the jeopardy 
of GVHD from solid organ grafts in the same way as it can do 
so after BMTx. 
REFERENCES 
1. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological 
and clinical aspects. Annu Rev Med 1984; 35: 11. 
2. Gale RP. Graft-versus-host disease. Immunol Rev 1985; 88: 193. 
3. McCloud AM, Thomson A W. FK 506: immunosuppressant for the 
1990's. Lancet 1991; 337:25. 
4. Gill TJ, Kunz HW, Misra DW, Cortese-Hassett AL. The major 
histocompatibility complex of the rat. Transplantation 1987; 43: 
773. 
5. Inomato T, Kunz HW, Gill TJ. Immunogenetic analysis of rat 
strains with recombinations in different regions of MHC. Im-
munogenetics 1988; 23: 133. 
6. Tutschka PJ, Beschorner WE, Allison AC, Burns WH, Santos 
GW. Use of cyclosporine A in allogeneic bone marrow transplan-
tation in the rat. Nature 1979; 20: 148. 
7. Markus PM, Cai X, Ming W, Demetris AJ, Fung JJ, Starzl TE. 
FK 506 reverses acute graft-versus-host disease following allo-
594 TRANSPLANTATION Vol. 52, No.4 
geneic bone marrow transplantation in rats. Surgery 1991; 110: 
357. 
8. Fung JJ, Todo S, Tzakis AG, et aJ. Current status of FK 506 in 
liver transplantation. Transplant Proc 1991; 23: 1902. 
9. Murase N, Kim DG, Todo S, Cramer DV, Fung JJ, Starzl TE. 
Suppression of allograft rejection with FK 506: I. Prolonged 
cardiac and liver survival in rats following short-course therapy. 
Transplantation 1990; 50: 186. 
10. Murase N, Demetris AJ, Matsuzaki T, et al. Long survival in rats 
after multivisceral versus isolated small bowel allotransplanta-
tion under FK 506. Surgery 1991; 110: 87. 
11. Iwaki Y, Starzl TE, Yagihashi A, et al. Replacement of donor 
lymphoid tissue in human small bowel transplants under FK 506 
immunosuppression. Lancet 1991; 337: 818. 
Received 2 November 1990. 
Accepted 14 February 1991. 
